Literature DB >> 15240194

Comfort care in severely disabled multiple sclerosis patients.

Marc Rousseaux1, Dominic Pérennou.   

Abstract

Comfort may be considered as the material aspect of well-being, and its limitation, defined as discomfort, exacerbates both the patient's and caregivers' difficulties. Discomfort results from the interaction of a patient's environment, treatment, and from the nature and severity of elementary deficits, such as spasticity, ranges of motion, pain, postural disorders, motor deficit and fatigue, bladder problems, insufficient ventilatory control, and also psychological difficulties. Although discomfort reduction may represent a major challenge in disabled persons, discomfort is usually underestimated in the assessment of deficiencies, disabilities, handicap, and even in quality of life (QOL) estimations. In this paper, we explain why discomfort may be a crucial problem in severe multiple sclerosis (MS) and argue for a systematic assessment of discomfort in the follow-up of the disease, especially in the following domains: dressing, washing, maintaining posture in a wheelchair and bed, food intake, mastication and swallowing, bowel control, urinary and feces emission, and also sexual life. The way to enhance comfort in MS patients is then analyzed.

Entities:  

Mesh:

Year:  2004        PMID: 15240194     DOI: 10.1016/j.jns.2004.04.002

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Experiences of quality of life in people with Multiple Sclerosis who are in a wheelchair.

Authors:  Stine Torp Løkkeberg; Gunnar Thoresen
Journal:  Nurs Open       Date:  2021-05-30

2.  Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity?

Authors:  Alessandro Murano Ferré Fernandes; André de Campos Duprat; Cláudia Alessandra Eckley; Leonardo da Silva; Roberta Busch Ferreira; Charles Peter Tilbery
Journal:  Braz J Otorhinolaryngol       Date:  2013-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.